VenatoRx Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- VenatoRx Pharmaceuticals's estimated annual revenue is currently $16.3M per year.
- VenatoRx Pharmaceuticals received $42.0M in venture funding in July 2017.
- VenatoRx Pharmaceuticals's estimated revenue per employee is $201,000
- VenatoRx Pharmaceuticals's total funding is $107M.
Employee Data
- VenatoRx Pharmaceuticals has 81 Employees.
- VenatoRx Pharmaceuticals grew their employee count by -4% last year.
VenatoRx Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | SVP Medical Sciences | Reveal Email/Phone |
3 | Controller | Reveal Email/Phone |
4 | VP, Microbiology | Reveal Email/Phone |
5 | SVP, Commercial Strategy | Reveal Email/Phone |
6 | VP, Non-Clinical Safety | Reveal Email/Phone |
7 | VP, R&D Program Management | Reveal Email/Phone |
8 | Director CMC | Reveal Email/Phone |
9 | Director, Technology and Information Systems | Reveal Email/Phone |
10 | Director, Clinical Science | Reveal Email/Phone |
VenatoRx Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.6M | 232 | 8% | N/A | N/A |
#2 | $84.2M | 419 | 3% | N/A | N/A |
#3 | $14.1M | 70 | 0% | N/A | N/A |
#4 | $1224.3M | 6091 | -9% | N/A | N/A |
#5 | $43.2M | 215 | -4% | N/A | N/A |
#6 | $12.3M | 61 | -6% | N/A | N/A |
#7 | $19.9M | 99 | 41% | N/A | N/A |
#8 | $16.5M | 82 | -5% | N/A | N/A |
#9 | $97.7M | 486 | 30% | N/A | N/A |
#10 | $12.5M | 62 | -16% | N/A | N/A |
What Is VenatoRx Pharmaceuticals?
Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of anti-infective products to address increasing medical needs. VenatoRx's lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$107M
Total Funding
81
Number of Employees
$16.3M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
VenatoRx Pharmaceuticals News
Venatorx Pharmaceuticals, Inc., a Malvern, PA-based private, clinical-stage pharmaceutical company focused on improving health outcomes for...
"Adaptive Phage Therapeutics and Venatorx Pharmaceuticals are poised to change the treatment landscape for drug-resistant infections," said AMR...
Venatorx is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant...
MALVERN, Pa.--(BUSINESS WIRE)--. VenatoRx Pharmaceuticals today announced that Joseph C. Larsen, Ph.D. has joined the Company as ...
Other Companies in Malvern
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 81 | 21% | N/A |
#2 | $16.7M | 83 | 30% | N/A |
#3 | $11.8M | 84 | 79% | N/A |
#4 | $7.5M | 84 | -12% | N/A |
#5 | $23.2M | 86 | 4% | N/A |
VenatoRx Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-07-26 | $42.0M | B | Versant Ventures | Article |